S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
S&P 500   5,093.50 (+0.47%)
DOW   38,984.16 (+0.09%)
QQQ   438.51 (+0.74%)
AAPL   181.68 (+0.14%)
MSFT   408.48 (+0.19%)
META   486.86 (+0.59%)
GOOGL   137.86 (+1.09%)
AMZN   174.07 (+0.53%)
TSLA   203.70 (+0.82%)
NVDA   793.72 (+2.20%)
NIO   5.69 (+4.79%)
AMD   182.12 (+3.16%)
BABA   74.88 (+0.39%)
T   17.07 (+0.65%)
F   12.40 (+0.81%)
MU   89.35 (-0.40%)
CGC   3.40 (+1.19%)
GE   155.45 (-0.10%)
DIS   111.87 (+0.97%)
AMC   4.63 (-7.21%)
PFE   27.13 (+0.33%)
PYPL   61.43 (+1.96%)
XOM   104.80 (+0.46%)
NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Price, News & Analysis

$3.47
+0.14 (+4.20%)
(As of 09:46 AM ET)
Today's Range
$3.20
$3.48
50-Day Range
$2.10
$4.83
52-Week Range
$1.08
$5.00
Volume
234,440 shs
Average Volume
1.73 million shs
Market Capitalization
$179.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.33

G1 Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
169.0% Upside
$9.33 Price Target
Short Interest
Bearish
6.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.44mentions of G1 Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$367,243 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.96) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

228th out of 958 stocks

Pharmaceutical Preparations Industry

101st out of 450 stocks


GTHX stock logo

About G1 Therapeutics Stock (NASDAQ:GTHX)

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Stock Price History

GTHX Stock News Headlines

Q4 2023 G1 Therapeutics Inc Earnings Call
G1 Therapeutics Inc (GTHX)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
GTHX Jul 2024 2.500 put
Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
GTHX Feb 2024 7.500 put
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
G1 Therapeutics, Inc. (GTHX)
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GTHX
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.33
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+180.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-147,560,000.00
Pretax Margin
-87.36%

Debt

Sales & Book Value

Annual Sales
$51.30 million
Book Value
$1.60 per share

Miscellaneous

Free Float
47,577,000
Market Cap
$172.63 million
Optionable
Optionable
Beta
1.74
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. John E. Bailey Jr. (Age 59)
    CEO, President & Director
    Comp: $1.06M
  • Mr. Mark Avagliano (Age 48)
    Chief Business Officer
    Comp: $628.54k
  • Mr. John W. Umstead V (Age 39)
    Chief Financial Officer
  • Mr. Terry L. Murdock (Age 64)
    Chief Operating Officer
    Comp: $541.59k
  • Mr. William C. Roberts (Age 55)
    Vice President of Investor Relations & Corporate Communications
  • Ms. Monica R. Thomas
    General Counsel & Chief Compliance Officer
  • Mr. Evan Hicks M.B.A.
    Vice President of Marketing
  • Dr. Rajesh K. Malik Ch.B. (Age 65)
    M.B., M.D., Chief Medical Officer
    Comp: $596.37k
  • Mr. Andrew Perry (Age 51)
    Chief Commercial Officer
    Comp: $568.6k
  • Mr. Jeff Macdonald
    Senior Director of Investor Relations & Corporate Communications














GTHX Stock Analysis - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price target for 2024?

4 brokers have issued 1 year price objectives for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $12.00. On average, they predict the company's stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 169.0% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2024?

G1 Therapeutics' stock was trading at $3.05 at the start of the year. Since then, GTHX shares have increased by 13.8% and is now trading at $3.47.
View the best growth stocks for 2024 here
.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 3,330,000 shares, an increase of 27.6% from the January 31st total of 2,610,000 shares. Based on an average trading volume of 1,820,000 shares, the short-interest ratio is currently 1.8 days.
View G1 Therapeutics' Short Interest
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.06. The business had revenue of $14.87 million for the quarter, compared to the consensus estimate of $12.83 million. G1 Therapeutics had a negative net margin of 90.82% and a negative trailing twelve-month return on equity of 132.03%. During the same quarter in the prior year, the business posted ($0.73) EPS.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.82%), Raymond James & Associates (1.09%), abrdn plc (0.82%), Needham Investment Management LLC (0.35%), Level Four Advisory Services LLC (0.34%) and Northern Trust Corp (0.24%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, John W V Umstead, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends
.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GTHX) was last updated on 2/29/2024 by MarketBeat.com Staff